4
Changes in Ownership
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Filed Acc 0001127602-22-008258
Corporate Executive VP & CFO sold 8,965 shares at an average $282.53 ($2,532,921)
- Corporate Executive VP & CFO acquired 8,965 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Smith David Ross Corporate Executive VP & CFO | 2022-03-03 | Option exercise | +3,846 | $109.34 | $420,522 | 29,665 | D |
| Smith David Ross Corporate Executive VP & CFO | 2022-03-03 | Option exercise | +3,304 | $144.67 | $477,990 | 32,969 | D |
| Smith David Ross Corporate Executive VP & CFO | 2022-03-03 | Option exercise | +1,815 | $179.66 | $326,083 | 34,784 | D |
| Smith David Ross Corporate Executive VP & CFO | 2022-03-03 | Sale | −3,825 | $281.49 | $1,076,716 | 30,959 | D |
| Smith David Ross Corporate Executive VP & CFO | 2022-03-03 | Sale | −2,606 | $282.56 | $736,361 | 28,353 | D |
| Smith David Ross Corporate Executive VP & CFO | 2022-03-03 | Sale | −1,289 | $283.41 | $365,316 | 27,064 | D |
| Smith David Ross Corporate Executive VP & CFO | 2022-03-03 | Sale | −858 | $284.58 | $244,171 | 26,206 | D |
| Smith David Ross Corporate Executive VP & CFO | 2022-03-03 | Sale | −387 | $285.16 | $110,357 | 25,819 | D |
| Derivatives | |||||||
| Smith David Ross Corporate Executive VP & CFO | 2022-03-03 | Option exercise · Stock Options (Right to Buy) | −3,846 | 0 | D | ||
| Smith David Ross Corporate Executive VP & CFO | 2022-03-03 | Option exercise · Stock Options (Right to Buy) | −3,304 | 3,305 | D | ||
| Smith David Ross Corporate Executive VP & CFO | 2022-03-03 | Option exercise · Stock Options (Right to Buy) | −1,815 | 5,446 | D | ||
| Open-market sales · 8,965 sh · avg $282.53 · $2,532,921 | |||||||
Loading xslF345X03/form4.xml…